Navigation Links
Experts Release New Cystic Fibrosis Guidelines
Date:11/15/2007

Includes updated info on which drugs work, which don't

THURSDAY, Nov. 15 (HealthDay News) -- Experts on Thursday issued new clinical standards for the treatment of cystic fibrosis (CF).

The guidelines were based on a two-year review of published research on patients aged six and older.

"Physicians treating patients with CF are faced with a growing number of treatment options. We are hopeful that clinicians will find these recommendations to be useful in their care of patients with CF," the guidelines' lead author, Dr. Patrick A. Flume, said in a prepared statement.

CF is a genetic disease that affects the lungs and other organs. It's characterized by thick, sticky mucus that makes it almost impossible for CF patients to fight off germs and infections. The disease is always fatal, and lung disease accounts for 85 percent of deaths among CF patients. However, advances in treatment in the last 60 years have increased life expectancy from just a few years to about 36 years.

Flume and his colleagues looked at a number of treatments and rated their effectiveness. Those with the strongest, most consistent results were given an "A" grade recommendation. They are:

  • Inhaled tobramycin -- an antibiotic -- to suppress chronic Pseudomonas aeruginosa infections in CF patients with moderate to severe disease, to improve lung function and reduce exacerbations.
  • Dornase alfa, which degrades the free DNA that accumulates in CF mucus, thereby loosening the mucus, promoting airway clearance, improving lung function and reducing exacerbations.

"B" grade recommendations were given for:

  • Inhaled tobramycin, to suppress Pseudomonas aeruginosa infections in CF patients with mild disease or who are asymptomatic, to reduce exacerbations.
  • Dornase alfa, for CF patients with mild disease who are asymptomatic, to improve lung function and reduce exacerbations.
  • Hypertonic saline, which hydrates surface liquid in patients with CF, thereby improving lung function and decreasing exacerbations.
  • Beta 2-adrenergic receptor agonists, which relax smooth muscles and dilate bronchial passages, which improve lung function in CF patients, and are well-tolerated.

The guidelines recommend against:

  • Systemic corticosteroids in children because of "an excess number of adverse events," including abnormalities in glucose metabolism, cataracts, and percentage of patients "colonized" with Pseudomonas. This recommendation excludes patients with concomitant asthma.
  • Inhaled corticosteroids, because there's no clinical benefit. This recommendation excludes patients who also have asthma, however.
  • Prophylactic anti-Staphylococcal antibiotics because of the lack of clinical efficacy and an apparent increase in P. aeruginosa infections with their use.

There wasn't sufficient evidence to recommend for or against other types of treatment, said Flume and his colleagues.

The guidelines are published in the second issue for November of the American Journal of Respiratory and Critical Care Medicine.

More information

The March of Dimes has more about cystic fibrosis.



-- Robert Preidt



SOURCE: American Thoracic Society, news release, Nov. 15, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Research Links TV/Video Game Playing With Child Obesity; Health Experts Back a New Approach
2. MultiVu Video Feed: PUBLIC HEALTH EXPERTS CONVENE TO DISCUSS THE TREATMENT AND PREVENTION OF RABIES
3. Health IT Event Draws Experts to the Pacific Northwest
4. Experts Sort Out Good Fats From Bad
5. Experts Offer Tips on Lung Cancer Prevention
6. March of Dimes, Experts for Moms and Babies, Launches Podcast
7. World fertility experts to meet in Montreal - IVF and IVM patients to provide first-person accounts at 14th World Congress
8. Bay IVF Experts Launch One of First East-West Fertility Programs of Its Kind
9. Experts propose cholesterol tests at 15 months of age
10. Experts Publish New Lung Disease Guidelines
11. Experts, Advocates Available to Comment on Hillary Clintons Health Care Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: